Form 4: CEO Edward Pershing Acquires Convertible Notes

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note and beneficially owns Series D-1 Convertible Preferred Stock, increasing his indirect ownership.

Summary

• Edward Pershing, CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), acquired an 8% Unsecured Convertible Promissory Note with a principal amount of $50,000.
• The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note was issued on March 25, 2026, as part of the Issuer's 2025 Financing.
• The note is exercisable from March 25, 2026, and expires on March 25, 2027.
• The outstanding principal and interest of the note will automatically convert into Series D-1 Preferred Stock at $2.862 per share on March 25, 2027 (12 months after issue date).
• Edward Pershing beneficially owns 17,471 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless converted earlier.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying, especially by a CEO, typically signals confidence in the company's future, although the specific financial terms and the size of the transaction should be considered in the broader context of the company's financial health.

Positives

• The acquisition of convertible notes by the CEO and Director, Edward Pershing, signals management's confidence in the company's future prospects.
• The transaction is part of the Issuer's 2025 Financing, indicating ongoing efforts to secure capital for operations and growth.

Future Outlook

The filing outlines future conversion events, including the automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock on March 25, 2027, and the subsequent automatic conversion of Series D-1 Preferred Stock into Common Stock on December 31, 2028.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a CEO and Director, are often interpreted by the market as a positive signal, indicating management's belief in the company's intrinsic value and future growth prospects. This transaction, part of a broader 2025 financing, suggests ongoing capital-raising activities within the biotechnology sector, which often requires significant investment for R&D and clinical trials.

Related Party Transactions

• Edward Pershing, who serves as both CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC., acquired an 8% Unsecured Convertible Promissory Note from the company. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may perceive the CEO's acquisition of convertible securities as a positive indicator of management's belief in the company's future performance and value.
• The financing activity supports the company's operations, which can benefit employees, suppliers, and other stakeholders by ensuring continued business activity.

Next Steps

• Voluntary or automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock by March 25, 2027.
• Voluntary or automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock by December 31, 2028.

Key Dates

Keywords

PROVECTUS BIOPHARMACEUTICALS, PVCT, SEC Form 4, Insider Transaction, Convertible Note, Preferred Stock, Beneficial Ownership, CEO, Director, Corporate Financing